secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0001171843-23-001948
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus reports Q4 net loss of $9.8M; identifies predictive biomarker for CPI-818 in T-cell lymphoma
--------------------------------------------------------------------------------

- Cash $42.3M at Dec 31, 2022 (from $69.5M); 2023 operating burn guided $19-22M with year-end cash $20-23M.
- Q4 2022 net loss $9.8M vs $9.2M year ago; R&D expense $4.1M.
- CPI-818 Phase 1/1b: ALC >900 biomarker identified; 4/8 biomarker-positive patients had objective responses.
- Median PFS 28.1 months in ALC>900 patients vs 2.1 months in ALC<900 patients (n=13 evaluable).
- Atopic dermatitis trial delayed to conserve cash; FDA meeting for Phase 3 lymphoma trial planned for 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184323001948/0001171843-23-001948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184323001948/f8k_032823.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-001948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer